End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 AUD | +12.50% | +5.88% | -10.00% |
04-30 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
04-10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 100.6 | 26.09 | 40.3 | 35.69 | 35.26 | 21.49 | - | - |
Enterprise Value (EV) 1 | 76.6 | 19.48 | 27.91 | 26.75 | 26.03 | 14.29 | 12.29 | 17.99 |
P/E ratio | -5.1 x | -1.89 x | -12.7 x | -16.1 x | -2.45 x | -1.64 x | -2 x | -6 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 8.26 x | 2.06 x | 1.7 x | 2.24 x | 1.83 x | 1.85 x | 5.97 x | 4.78 x |
EV / Revenue | 6.29 x | 1.54 x | 1.18 x | 1.68 x | 1.35 x | 1.23 x | 3.41 x | 4 x |
EV / EBITDA | -4.89 x | -1.61 x | -124 x | -2.61 x | -3.21 x | -1.86 x | -0.96 x | -4.5 x |
EV / FCF | -3.69 x | -1.41 x | 11.5 x | -1.65 x | - | -2.51 x | -1.18 x | -4.28 x |
FCF Yield | -27.1% | -71.2% | 8.7% | -60.4% | - | -39.9% | -84.6% | -23.3% |
Price to Book | - | - | - | 3.3 x | 3.69 x | - | - | - |
Nbr of stocks (in thousands) | 394,316 | 395,249 | 452,824 | 549,078 | 719,584 | 1,194,032 | - | - |
Reference price 2 | 0.2550 | 0.0660 | 0.0890 | 0.0650 | 0.0490 | 0.0180 | 0.0180 | 0.0180 |
Announcement Date | 25/07/19 | 31/07/20 | 28/07/21 | 29/07/22 | 28/08/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 12.17 | 12.66 | 23.68 | 15.91 | 19.31 | 11.6 | 3.6 | 4.5 |
EBITDA 1 | -15.65 | -12.08 | -0.225 | -10.25 | -8.114 | -7.7 | -12.8 | -4 |
EBIT 1 | -18.27 | -15.32 | -3.377 | -13.48 | -9.962 | -8.1 | -13.2 | -4.4 |
Operating Margin | -150.11% | -120.93% | -14.26% | -84.74% | -51.6% | -69.83% | -366.67% | -97.78% |
Earnings before Tax (EBT) 1 | - | - | - | -1.93 | -11.36 | -8.2 | -13.3 | -4.5 |
Net income 1 | -20.06 | -13.94 | -2.97 | -1.93 | -11.36 | -8.2 | -13.3 | -4.5 |
Net margin | -164.8% | -110.09% | -12.54% | -12.13% | -58.84% | -70.69% | -369.44% | -100% |
EPS 2 | -0.0500 | -0.0350 | -0.007000 | -0.004030 | -0.0200 | -0.0110 | -0.009000 | -0.003000 |
Free Cash Flow 1 | -20.78 | -13.86 | 2.428 | -16.17 | - | -5.7 | -10.4 | -4.2 |
FCF margin | -170.73% | -109.42% | 10.26% | -101.6% | - | -49.14% | -288.89% | -93.33% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 25/07/19 | 31/07/20 | 28/07/21 | 29/07/22 | 28/08/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2023 Q2 | 2023 S2 |
---|---|---|---|---|---|---|
Net sales | 4.021 | 8.644 | 13.69 | 9.989 | - | 10.15 |
EBITDA | -7.999 | -4.081 | 0.713 | -0.938 | - | - |
EBIT | -9.615 | -5.701 | -0.876 | -2.501 | - | - |
Operating Margin | -239.12% | -65.95% | -6.4% | -25.04% | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - |
Net income 1 | -10.32 | -3.624 | 0.046 | -3.016 | -4.786 | - |
Net margin | -256.63% | -41.93% | 0.34% | -30.19% | - | - |
EPS 2 | - | - | - | -0.007000 | -0.000100 | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 31/01/20 | 31/07/20 | 29/01/21 | 28/07/21 | 10/02/23 | 28/08/23 |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 24 | 6.61 | 12.4 | 8.94 | 9.23 | 7.2 | 9.2 | 3.5 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -20.8 | -13.9 | 2.43 | -16.2 | - | -5.7 | -10.4 | -4.2 |
ROE (net income / shareholders' equity) | - | - | - | - | -112% | - | - | - |
ROA (Net income/ Total Assets) | -39% | -31.7% | -8.61% | -6.57% | -46.2% | - | - | - |
Assets 1 | 51.38 | 44.04 | 34.5 | 29.39 | 24.61 | - | - | - |
Book Value Per Share | - | - | - | 0.0200 | 0.0100 | - | - | - |
Cash Flow per Share 2 | - | - | - | -0.0300 | -0.0100 | -0.0100 | -0.0100 | -0 |
Capex 1 | 0.58 | 0.26 | 0.33 | 0.07 | 0.14 | 0.1 | 0.1 | - |
Capex / Sales | 4.73% | 2.05% | 1.4% | 0.41% | 0.71% | 0.86% | 2.78% | - |
Announcement Date | 25/07/19 | 31/07/20 | 28/07/21 | 29/07/22 | 28/08/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.00% | 14.13M | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.68% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- SNT Stock
- Financials Syntara Limited